Rigel Pharma Buys US Rights for Gavreto

Rigel Pharma buys US rights to Gavreto from Blueprint Medicines

Overview

Rigel Pharmaceuticals, Inc. (Rigel) announced that it has entered into a definitive agreement to acquire the US rights to Gavreto (pralsetinib) from Blueprint Medicines Corporation (Blueprint).

Gavreto is a once daily, small molecule, oral, kinase inhibitor of wild-type RET (rearranged during transfection) and oncogenic RET fusions. Gavreto is approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

Statemens from Rigel on NSCLC

• "NSCLC is the most common type of lung cancer in the US with RET fusions representing 1-2% of the patient population. Gavreto is a targeted treatment option with an established safety profile that has shown durable responses in RET fusion-positive NSCLC patients and represents a compelling addition to our commercial portfolio," said Raul Rodriguez, Rigel's president and CEO. 

• "We are excited about this transaction, as we continue to realize our corporate strategy to grow our haematology and oncology business while leveraging our existing commercial and medical affairs infrastructure and expertise. Gavreto is the third commercial product in our portfolio, supporting top line growth and our commitment to providing differentiated therapies to patients in need."

• "Gavreto is one of only two approved RET inhibitors on the market for patients. We are confident in our ability to effectively transition Gavreto to our distribution network and utilize our robust capabilities to enable both existing and new patients to continue to have access to this important treatment option,"" said Dave Santos, Rigel's chief commercial officer. 

• "The addition of Gavreto will be highly synergistic with our current product portfolio, leveraging our existing commercial infrastructure and enabling us to expand into solid tumours."

Indications for Gavreto

• Gavreto is also approved for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). 

• This indication was approved under accelerated approval based on overall response rate and duration of response. 

• Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). 

• Discussions with the FDA regarding confirmatory requirements are ongoing.

Terms of Agreement

• Under the terms of the agreement, Blueprint will receive a purchase price of $15.0 million, $10.0 million of which is payable upon first commercial sale by Rigel and an additional $5.0 million of which is payable on the first anniversary of the closing date, subject to certain conditions. 

• Blueprint is also eligible to receive up to $97.5 million in future commercial milestone payments and up to $5.0 million in future regulatory milestone payments, in addition to tiered royalties ranging from 10% to 30%. 

• Patents that have issued or are expected to issue covering Gavreto will have statutory expiration dates between 2036 and 2041. 

• Rigel expects to complete the transition of the asset and start recognizing product sales in the third quarter of 2024. 

• Rigel will provide additional details on this transaction at its upcoming quarterly earnings call in early March.

Related to Acquisition

• Rigel's acquisition of the US rights to Gavreto is concurrent to a previously announced Roche decision to terminate the Gavreto collaboration agreement with Blueprint effective February 22, 2024. 

• According to a statement from the company, Genentech, a member of the Roche Group, is committed to patients and working with Rigel and Blueprint to ensure current and newly prescribed patients can access Gavreto without interruption through the transition period, with specific next steps and timing to be communicated to key stakeholders, including healthcare providers, in the next few weeks.

Lung cancer: Epidemiology

• It is estimated that over 230,000 adults in the US will be diagnosed with lung cancer in 2024.  

• Lung cancer is the leading cause of cancer death in the US, with NSCLC being the most common type accounting for 80-85% of all lung cancer diagnoses. 

• RET fusions are implicated in approximately 1-2% of patients with NSCLC.

Uses of Drug

Gavreto (pralsetinib) is indicated for the treatment of: Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test; Adult and paediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

About Company 

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!